|
EP0170269A3
(en)
|
1984-08-02 |
1987-09-23 |
Kao Corporation |
Medicated cosmetic compositions
|
|
US5358866A
(en)
|
1991-07-03 |
1994-10-25 |
The United States Of America As Represented By The Department Of Health And Human Services |
Cytosine deaminase negative selection system for gene transfer techniques and therapies
|
|
US5846945A
(en)
|
1993-02-16 |
1998-12-08 |
Onyx Pharmaceuticals, Inc. |
Cytopathic viruses for therapy and prophylaxis of neoplasia
|
|
FR2705361B1
(fr)
|
1993-05-18 |
1995-08-04 |
Centre Nat Rech Scient |
Vecteurs viraux et utilisation en thérapie génique.
|
|
ES2310924T3
(es)
|
1993-07-13 |
2009-01-16 |
Centelion |
Vectores adenovirales defectivos y utilizacion en terapia genica.
|
|
US5631236A
(en)
|
1993-08-26 |
1997-05-20 |
Baylor College Of Medicine |
Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
|
|
US5595756A
(en)
*
|
1993-12-22 |
1997-01-21 |
Inex Pharmaceuticals Corporation |
Liposomal compositions for enhanced retention of bioactive agents
|
|
US5830686A
(en)
|
1994-01-13 |
1998-11-03 |
Calydon |
Tissue-specific enhancer active in prostate
|
|
US5677170A
(en)
|
1994-03-02 |
1997-10-14 |
The Johns Hopkins University |
In vitro transposition of artificial transposons
|
|
US5587299A
(en)
|
1994-04-20 |
1996-12-24 |
Memorial Sloan-Kettering Cancer Center |
Isolated nucleic acid molecule coding for fibroblast activation protein alpha and uses thereof
|
|
US7732129B1
(en)
|
1998-12-01 |
2010-06-08 |
Crucell Holland B.V. |
Method for the production and purification of adenoviral vectors
|
|
US5877011A
(en)
|
1996-11-20 |
1999-03-02 |
Genzyme Corporation |
Chimeric adenoviral vectors
|
|
CN1242051A
(zh)
|
1996-12-31 |
2000-01-19 |
昂尼克斯药物公司 |
用于肿瘤治疗和预防的致细胞病变病毒
|
|
DE69838510T2
(de)
|
1997-02-20 |
2008-07-03 |
Johns Hopkins University School Of Medicine |
Mutationen in atp-abhängigen transpositionsproteinen die die zielortspezifität reduzieren
|
|
US20030044384A1
(en)
|
1997-10-09 |
2003-03-06 |
Pro-Virus, Inc. |
Treatment of neoplasms with viruses
|
|
NZ518945A
(en)
|
1997-10-09 |
2007-03-30 |
Wellstat Biologics Corp |
Treatment of neoplasms with viruses
|
|
US6291214B1
(en)
|
1998-05-11 |
2001-09-18 |
Glaxo Wellcome Inc. |
System for generating recombinant viruses
|
|
US20020019051A1
(en)
|
1998-05-27 |
2002-02-14 |
Monika Lusky |
Chimeric adenoviral vectors
|
|
US20030017138A1
(en)
|
1998-07-08 |
2003-01-23 |
Menzo Havenga |
Chimeric adenoviruses
|
|
CN1110553C
(zh)
|
1998-07-15 |
2003-06-04 |
杭州赛狮生物技术开发有限公司 |
基因工程腺病毒及其用途
|
|
CA2342396A1
(en)
|
1998-09-11 |
2000-03-23 |
Genvec, Inc. |
Alternatively targeted adenovirus
|
|
EP1137792B9
(en)
|
1998-12-09 |
2007-12-12 |
The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services |
A recombinant vector expressing multiple costimulatory molecules and uses thereof
|
|
ATE332364T1
(de)
|
1999-02-22 |
2006-07-15 |
Transgene Sa |
Verfahren zur gewinnung von purifizierter virenzuammensetzung
|
|
HK1045716A1
(zh)
|
1999-04-09 |
2002-12-06 |
阿文蒂斯药物股份有限公司 |
用於保存感染性重組腺病毒的組合物
|
|
EP1816204B1
(en)
|
1999-05-17 |
2010-10-20 |
Crucell Holland B.V. |
Recombinant Adenovirus of the Ad26 serotype
|
|
EP1181382B1
(en)
|
1999-06-01 |
2005-03-23 |
The University of Washington |
Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
|
|
DE60039766D1
(de)
|
1999-08-09 |
2008-09-18 |
Targeted Genetics Corp |
Terologen nukleotidsequenz von einem rekombinanten viralen vektor durch ausgestaltung der sequenz in einer art und weise, dass basenpaarungen innerhalb der sequenz entstehen
|
|
US7396679B2
(en)
|
1999-11-15 |
2008-07-08 |
Onyx Pharmaceuticals, Inc. |
Oncolytic adenovirus
|
|
KR100802403B1
(ko)
|
2000-01-21 |
2008-02-13 |
바이오벡스 리미티드 |
바이러스 주
|
|
US7456009B2
(en)
|
2000-03-07 |
2008-11-25 |
Merck & Co., Inc. |
Adenovirus formulations
|
|
EP1301612A2
(en)
|
2000-05-31 |
2003-04-16 |
Genvec, Inc. |
Method and composition for targeting an adenoviral vector
|
|
US6965018B2
(en)
|
2000-06-06 |
2005-11-15 |
Bristol-Myers Squibb Company |
Antibodies directed to B7-related polypeptide, BSL-2
|
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
|
EP1348030B1
(en)
|
2001-01-04 |
2009-11-25 |
Wadell, Göran |
Viral vector for gene therapy
|
|
US20050175589A1
(en)
|
2001-07-13 |
2005-08-11 |
Btg International Limited |
Anti-neoplastic viral agents
|
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
|
EP1327688A1
(en)
|
2002-01-14 |
2003-07-16 |
Vereniging Voor Christelijk Wetenschappelijk Onderwijs |
Adenoviruses with enhanced lytic potency
|
|
AU2003206815A2
(en)
|
2002-02-01 |
2003-09-02 |
Transgene S.A. |
Adenoviral vectors for modulating the cellular activities associated with PODs
|
|
US7858367B2
(en)
|
2002-04-30 |
2010-12-28 |
Duke University |
Viral vectors and methods for producing and using the same
|
|
US20040167088A1
(en)
|
2003-02-25 |
2004-08-26 |
Genvec, Inc. |
Method of using adenoviral vectors with increased persistence in vivo
|
|
US20040213764A1
(en)
|
2003-03-28 |
2004-10-28 |
William Wold |
Adenovirus replication-competent vectors expressing trail
|
|
US20050136035A1
(en)
|
2003-06-03 |
2005-06-23 |
Derek Ko |
Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
|
|
CA2527369A1
(en)
|
2003-07-18 |
2005-02-03 |
Onyx Pharmaceuticals, Inc. |
Subgroup b adenoviral vectors for treating disease
|
|
KR101229731B1
(ko)
|
2003-10-16 |
2013-03-07 |
암젠 리서치 (뮌헨) 게엠베하 |
다중특이적 탈면역화된 ｃｄ3-바인더
|
|
WO2005086922A2
(en)
|
2004-03-10 |
2005-09-22 |
Board Of Regents, University Of Texas System |
Oncolytic adenovirus armed with therapeutic genes
|
|
WO2005107474A2
(en)
|
2004-04-30 |
2005-11-17 |
Introgen Therapeutics, Inc. |
Oncolytic adenovirus armed with therapeutic genes
|
|
WO2005118825A2
(en)
|
2004-05-26 |
2005-12-15 |
Schering Aktiengesellschaft |
Chimeric adenoviruses for use in cancer treatment
|
|
US20060292682A1
(en)
|
2004-07-22 |
2006-12-28 |
Hawkins Lynda K |
Addition of transgenes into adenoviral vectors
|
|
WO2006039045A2
(en)
|
2004-09-01 |
2006-04-13 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Adenoviral vectors able to transduce apcs, potential use in immune response generation
|
|
EP1819823A2
(en)
|
2004-12-01 |
2007-08-22 |
Bayer Schering Pharma Aktiengesellschaft |
Generation of replication competent viruses for therapeutic use
|
|
WO2007027860A2
(en)
|
2005-08-31 |
2007-03-08 |
Genvec, Inc. |
Adenoviral vector-based malaria vaccines
|
|
DE102005055128B4
(de)
|
2005-11-15 |
2015-04-02 |
Universität Rostock |
Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor
|
|
ES2304281B1
(es)
|
2006-02-01 |
2009-08-12 |
Dnatrix Inc. |
Adenovirus oncoliticos para el tratamiento del cancer.
|
|
WO2008080003A2
(en)
|
2006-12-22 |
2008-07-03 |
Bayer Schering Pharma Aktiengesellschaft |
Generation of oncolytic adenoviruses and uses thereof
|
|
US20110034560A1
(en)
|
2008-01-29 |
2011-02-10 |
Sven Jacobson |
Liquid formulations of compounds active at sulfonylurea receptors
|
|
MX339014B
(es)
|
2008-05-27 |
2016-05-09 |
Oncolytics Biotech Inc |
Modulacion de presion intersticial y suministro y distribucion viral oncolitica.
|
|
BRPI0919840B1
(pt)
|
2008-10-01 |
2023-02-28 |
Amgen Research (Munich) Gmbh |
Molécula de anticorpo de cadeia única biespecífica, seu uso, e composição farmacêutica que a compreende
|
|
CN101381742A
(zh)
|
2008-10-23 |
2009-03-11 |
浙江理工大学 |
晚期启动子靶向性调控溶瘤腺病毒pCN305载体及其构建方法与应用
|
|
ES2385251B1
(es)
|
2009-05-06 |
2013-05-06 |
Fundació Privada Institut D'investigació Biomèdica De Bellvitge |
Adenovirus oncolíticos para el tratamiento del cáncer.
|
|
US20100297072A1
(en)
|
2009-05-19 |
2010-11-25 |
Depinho Ronald A |
Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
|
|
CA2776037A1
(en)
|
2009-10-02 |
2011-04-07 |
Ludwig Institute For Cancer Research Ltd |
Anti-fibroblast activation protein antibodies and methods and uses thereof
|
|
WO2011043719A1
(en)
|
2009-10-05 |
2011-04-14 |
Ya-Fang Mei |
Replicating viral vectors for gene therapy
|
|
EP2606127B1
(en)
|
2010-08-16 |
2019-03-20 |
Salk Institute For Biological Studies |
Adenoviral assembly method
|
|
EP2619312A1
(en)
|
2010-09-24 |
2013-07-31 |
Oncos Therapeutics Oy |
Oncolytic adenoviral vectors coding for monoclonal anti - ctla - 4 antibodies
|
|
PT2748201T
(pt)
|
2011-08-23 |
2018-02-08 |
Roche Glycart Ag |
Moléculas de ligação ao antigénio biespecíficas que ativam as células t
|
|
JP2015507604A
(ja)
|
2011-11-14 |
2015-03-12 |
リジェネレイティブ サイエンシーズ， エルエルシー |
懸濁粒子送達システムおよび方法
|
|
CN102586327B
(zh)
|
2012-01-18 |
2013-09-11 |
陕西师范大学 |
一步法构建携带外源基因的d24纤维蛋白修饰的条件复制型腺病毒载体及其应用
|
|
NZ701324A
(en)
|
2012-05-04 |
2016-09-30 |
Pfizer |
Prostate-associated antigens and vaccine-based immunotherapy regimens
|
|
WO2014138314A1
(en)
|
2013-03-05 |
2014-09-12 |
Baylor College Of Medicine |
Oncolytic virus
|
|
GB201322851D0
(en)
*
|
2013-12-23 |
2014-02-12 |
Psioxus Therapeutics Ltd |
Method
|
|
GB2519564A
(en)
|
2013-10-24 |
2015-04-29 |
Shared Band Ltd |
Multicast transmission over bonded broadband
|
|
GB201318793D0
(en)
|
2013-10-24 |
2013-12-11 |
Plaquetec Ltd |
Vascular Biomarkers
|
|
TR201802728T4
(tr)
|
2013-10-25 |
2018-03-21 |
Psioxus Therapeutics Ltd |
Heterolog genlerle donatılmış onkolitik adenovirüsler.
|
|
CA2931322A1
(en)
|
2013-11-22 |
2015-05-28 |
Dnatrix, Inc. |
Adenovirus expressing immune cell stimulatory receptor agonist(s)
|
|
CA2944647C
(en)
|
2014-04-03 |
2025-07-08 |
Igm Biosciences Inc |
MODIFIED J STRING
|
|
GB201406608D0
(en)
*
|
2014-04-12 |
2014-05-28 |
Psioxus Therapeutics Ltd |
Virus
|
|
WO2016030489A2
(en)
|
2014-08-27 |
2016-03-03 |
Psioxus Therapeutics Limited |
A process for the production of adenovirus
|
|
GB201503500D0
(en)
|
2015-03-02 |
2015-04-15 |
Ucl Business Plc |
Cell
|
|
CN107406859A
(zh)
|
2015-03-17 |
2017-11-28 |
倾斜生物医疗公司 |
编码双特异性抗体的溶瘤腺病毒及与其相关的方法和用途
|
|
BR122018004815A2
(pt)
|
2015-04-30 |
2019-09-10 |
Psioxus Therapeutics Ltd |
adenovírus oncolítico que codifica proteína b7
|
|
EA201891022A1
(ru)
|
2015-12-17 |
2019-01-31 |
Псайоксус Терапьютикс Лимитед |
Вирус, кодирующий антитело к комплексу tcr или фрагмент указанного антитела
|
|
JP2019508044A
(ja)
|
2016-03-18 |
2019-03-28 |
ナントセル，インコーポレイテッド |
樹状細胞感染のための多モードベクター
|
|
CN119614520A
(zh)
|
2016-08-29 |
2025-03-14 |
阿卡米斯生物公司 |
携带双特异性t细胞衔接器的腺病毒
|
|
GB201713765D0
(en)
|
2017-08-28 |
2017-10-11 |
Psioxus Therapeutics Ltd |
Modified adenovirus
|
|
AU2017345764A1
(en)
|
2016-10-20 |
2019-05-02 |
Alpine Immune Sciences, Inc. |
Secretable variant immunomodulatory proteins and engineered cell therapy
|
|
WO2018083257A1
(en)
|
2016-11-03 |
2018-05-11 |
Psioxus Therapeutics Limited |
Oncolytic adenovirus encoding transgenes
|
|
WO2018083259A1
(en)
|
2016-11-03 |
2018-05-11 |
Psioxus Therapeutics Limited |
Oncolytic adenovirus encoding transgenes
|
|
WO2018083258A1
(en)
|
2016-11-03 |
2018-05-11 |
Psioxus Therapeutics Limited |
Oncolytic adenovirus encoding at least three transgenes
|
|
GB201801614D0
(en)
|
2018-01-31 |
2018-03-14 |
Psioxus Therapeutics Ltd |
Formulation
|